Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.

ABSTRACT:

Background

The incidence of type 2 diabetes in pregnancy is rising and rates of serious adverse maternal and fetal outcomes remain high. Metformin is a biguanide that is used as first-line treatment for non-pregnant patients with type 2 diabetes. We hypothesize that metformin use in pregnancy, as an adjunct to insulin, will decrease adverse outcomes by reducing maternal hyperglycemia, maternal insulin doses, maternal weight gain and gestational hypertension/pre-eclampsia. In addition, since metformin crosses the placenta, metformin treatment of the fetus may have a direct beneficial effect on neonatal outcomes. Our aim is to compare the effectiveness of the addition of metformin to insulin, to standard care (insulin plus placebo) in women with type 2 diabetes in pregnancy.

Metho

SUBMITTER: Feig DS 

PROVIDER: S-EPMC4952061 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature